TFE3 is altered in 2.44% of renal cell carcinoma patients [3].

TFE3 is an inclusion criterion in 3 clinical trials for renal cell carcinoma, of which 1 is open and 2 are closed. Of the trials that contain TFE3 status and renal cell carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 2 are phase 2 (1 open) [4].

TFE3 is altered in 60.71% of translocation-associated renal cell carcinoma patients [3].

TFE3 is an inclusion criterion in 2 clinical trials for translocation-associated renal cell carcinoma, of which 1 is open and 1 is closed. Of the trials that contain TFE3 status and translocation-associated renal cell carcinoma as inclusion criteria, 2 are phase 2 (1 open) [4].

TFE3 is altered in 1.25% of papillary renal cell carcinoma patients [3].

TFE3 is an inclusion criterion in 2 clinical trials for papillary renal cell carcinoma, of which 2 are open and 0 are closed. Of the trials that contain TFE3 status and papillary renal cell carcinoma as inclusion criteria, 2 are phase 2 (2 open) [4].

TFE3 is altered in 6.67% of non-clear cell renal cell carcinoma patients [3].

TFE3 is an inclusion criterion in 2 clinical trials for non-clear cell renal cell carcinoma, of which 2 are open and 0 are closed. Of the trials that contain TFE3 status and non-clear cell renal cell carcinoma as inclusion criteria, 2 are phase 2 (2 open) [4].

TFE3 is altered in 0.54% of malignant solid tumor patients [3].

TFE3 is an inclusion criterion in 2 clinical trials for malignant solid tumor, of which 1 is open and 1 is closed. Of the trials that contain TFE3 status and malignant solid tumor as inclusion criteria, 2 are phase 1 (1 open) [4].

TFE3 is an inclusion criterion in 2 clinical trials for chromophobe renal cell carcinoma, of which 2 are open and 0 are closed. Of the trials that contain TFE3 status and chromophobe renal cell carcinoma as inclusion criteria, 2 are phase 2 (2 open) [4].

TFE3 is an inclusion criterion in 2 clinical trials for unclassified renal cell carcinoma, of which 2 are open and 0 are closed. Of the trials that contain TFE3 status and unclassified renal cell carcinoma as inclusion criteria, 2 are phase 2 (2 open) [4].

TFE3 is altered in 0.95% of soft tissue sarcoma patients [3].

TFE3 is an inclusion criterion in 1 clinical trial for soft tissue sarcoma, of which 1 is open and 0 are closed. Of the trial that contains TFE3 status and soft tissue sarcoma as inclusion criteria, 1 is phase 1 (1 open) [4].

TFE3 is altered in 0.47% of non-hodgkin lymphoma patients [3].

TFE3 is an inclusion criterion in 1 clinical trial for non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains TFE3 status and non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) [4].

TFE3 is an inclusion criterion in 1 clinical trial for sarcomatoid renal cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains TFE3 status and sarcomatoid renal cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].